Gland Pharma’s ₹6.29 Crore GST Dispute: What Investors Need to Know Introduction
Explore Gland Pharma’s ₹6.29 crore GST dispute from Telangana authorities over export reclassifications and credit notes for FY 2019-20. The company deems it unjustified and plans an appeal, assuring no major impact. Dive into company overview, market reactions, stock performance, and broader pharma sector implications as of March 9, 2026. Solid fundamentals persist amid short-term volatility.
